CFO's First Check Lands With RSI at 26

ISB Research · Favorable · sent to Ultimate members October 1, 2026

Xenon is a neuroscience biotech with its lead drug, azetukalner, in Phase 3 for epilepsy. The CFO just wrote his first-ever buy here, $559,740 at $37.32, and he did it with the stock down 45% from its high and sitting near the bottom of its yearly range. RSI at 26 and MFI under 30 tell you the tape is washed out, and a finance chief writing his first check into that kind of weakness is the kind of signal the data respects. The catch: the broad market is under its own short-term trend in a risk-off week, and the washout edge has been weaker when the tape is falling, so don't expect a clean V. A trader who agrees with him could sell a put spread beneath $37.32 to get paid to wait, maybe for a cheaper entry than the man who signs the checks.

Ultimate members received this analysis in real time.